OPKO Health Inc. (NASDAQ:OPK) is moving in a range. The company reported its financial results and business update for the quarter ended June 30, 2021. OPK indicated that test volume at BioReference laboratories was up 325 relative to Q2 2020.
During the quarter, the company processed around 2.8 million COVID-19 PCR tests, and currently, it has a daily processing capacity of over 100,000 PCR tests. Equally, in Q2, BRL conducted approximately 132,000 COVID-19 serology tests measuring SARS-CoV-2 antibody levels.
In June, BRL unveiled a COVID-19 customized test program for crew and guests cruising with Royal Caribbean Group to help offer a safe traveling environment for crew and guests. In April, it had entered a testing agreement for staff and players, league staff, and stadium employees for the Major league Baseball season and the 2021/22 NFL season. Equally, OPKO executed a deal with Nicoya Therapeutics to produce and market RAYALDEE across Greater China. In addition, the company sold one of its sterile fill-and-finish facilities in Waterford, Ireland, to Horizon Therapeutics Plc. So in months to come, OPK is a stock to watch.
On Monday, OPK stock decreased 1% at $3.64 with more than 3.35 million shares, compared to its average volume of 4.18 million shares. The stock has moved within a range of $3.5800 – 3.7250 after opening the trade at $3.68.